Abstract
“Double-blind, randomized control trials have become the hallmark of therapeutic respectability” (1). From small beginnings some thirty years ago, clinical trials have come to take an increasingly large place in medical research and, indeed, the research budget. In their heyday, in the early 1970s, it was fashionable to suggest that all new methods of management should be submitted to this discipline and those who were reluctant to do so were castigated fiercely by statisticians and community physicians. Cardiologists, in particular, have been the butt of these complaints, notwithstanding the fact that many of the leaders of the subspeciality were early in the field in studies of anticoagulant therapy. Perhaps it was the disillusionment occasioned by this experience that made their colleagues too reluctant for a time to embark on further experiments of the same kind.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Editorial - Controlled Trials: planned deception? Lancet 1:534–535, 1979.
Peto R: Clinical trial methodology. Biomedicine Special Issue 28:24–36, 1978.
Peto M, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SW, Mantel N, McPherson K, Peto J, and Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer 34:585–612, 1976.
Peto M, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, and Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer 35:1–39, 1977.
Freiman JA, Chalmers TC, Smith H, and Kuebler RR: The importance of beta, the Type II error and sample size in the design and interpretation of the randomized control trials. New England Journal of Medicine 299:690–694, 1978.
Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, and Werko L: Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Lancet 2, 1157–1157, 1974.
Multicentre International Study: Improvement in prognosis of myocardial infarction by long-term betaadrenoreceptor blockade using practolol. British Medical Journal 3:735–740, 1975.
The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of Medicine 298:289–295, 1978.
European Coronary Surgery Study Group. Coronary artery bypass surgery in stable angina pectoris. Lancet, 1:889–894, 1979.
Hultgren HN, Takaro T, Detre K and participants in the Veterans Administration Cooperative Study: Veterans Administration Cooperative Study of surgical treatment of stable angina and preliminary results. In Rahimtoola SH (ed), Coronary Bypass Surgery, FA Davis, Philadelphia, 1977.
Lovell RRH: Review of the present status of drug treatment for preventing sudden death. British Heart Journal, 40:(suppl) 94, 1978.
Reynolds JL, and Whitlock EML: Effects of a beta-adrenergic blocker in myocardial infarction treated for one year from onset. British Heart Journal 34:252–259, 1972.
Barber JM, Boyle DMcC, Chaturvedi NC, Singh N, and Walsh MJ: Practolol in acute myocardial infarction. Acta Medica Scandinavica (suppl) 587:213–216, 1976.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Martinus Nijhoff Publishers bv, The Hague
About this chapter
Cite this chapter
Julian, D.G. (1980). Critical Analysis of Intervention Studies: Methodological Problems and Pitfalls. In: Kulbertus, H.E., Wellens, H.J.J. (eds) Sudden Death. Developments in Cardiovascular Medicine, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8834-7_19
Download citation
DOI: https://doi.org/10.1007/978-94-009-8834-7_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8836-1
Online ISBN: 978-94-009-8834-7
eBook Packages: Springer Book Archive